Abbott Laboratories
ABT
NYSE98.05
Abbott Laboratories
NYSE:ABT
RECENT
PRICE
98.05
P/E
RATIO
25.39
(PEG:-12.66)
P/E RATIO
RELATIVE
TO S&P
1.20
DIV
YLD
1.92%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.67 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 03/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Fiscal year
14.69
1.12
2.61
1.16
16.79
2.34
2.29
1.27
19.13
3.16
3.92
1.41
19.89
3.72
4.00
1.56
22.73
2.99
4.99
1.73
24.74
3.01
4.76
1.87
25.29
3.78
4.77
2.02
14.11
1.66
1.41
0.57
13.43
1.51
1.72
0.89
13.86
3.00
1.26
0.98
14.16
0.95
1.41
1.04
15.71
0.27
2.54
1.06
17.42
1.35
2.79
1.12
18.10
2.09
2.55
1.29
19.54
2.54
3.23
1.45
24.32
3.99
4.88
1.81
24.65
3.91
4.41
1.87
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.87
9.19
1.07
11.52
0.83
11.32
0.70
14.78
0.66
14.47
0.95
15.56
1.14
16.95
0.74
16.26
0.71
14.27
0.75
14.40
0.76
13.94
0.65
17.72
0.79
17.39
0.93
17.64
1.23
18.51
1.06
20.21
1.00
20.71
CAPEX per share
Book Value per share
1,530
1,543
1,544
1,546
1,547
1,570
1,577
1,548
1,508
1,473
1,473
1,744
1,756
1,763
1,771
1,771
1,771
Comm.Shares outs.(m)
- -
- -
- -
11.2
0.65
4.85%
8.3
0.39
5.37%
6.2
0.09
6.74%
8.1
0.39
7.11%
8.1
0.50
7.66%
7.9
0.53
6.72%
21.3
1.25
1.60%
27.0
1.49
2.18%
15.3
0.77
2.13%
42.4
1.91
2.59%
177.2
7.51
2.19%
47.6
1.91
1.75%
38.3
1.58
1.61%
37.7
0.99
1.51%
30.5
1.02
1.49%
28.5
1.34
1.68%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/12/22 | Q4)
Total liabilities
$219 m.
Total assets
$74,438 m.
Long-term debt
$22,044 m.
Cash and equiv.
$9,882 m.
Goodwill $22,799 m.
Retained earnings $41,770 m.
Common stock 1,744 m. shares
Market Capitalisation
$171,205 m. (as of 25/3/23)
38,851
14.8%
39,874
20.3%
21,848
12.0%
20,247
12.8%
20,405
14.1%
20,853
15.3%
27,390
6.3%
30,578
11.9%
31,904
14.2%
34,608
15.5%
43,075
19.6%
43,653
19.2%
Revenue (m)
Operating margin
3,044
4,728
2,783
5,963
1,719
2,576
1,548
2,284
1,472
4,423
1,353
1,400
3,021
477
3,278
2,368
3,014
3,687
3,327
4,495
3,538
7,071
2,013
6,933
Depreciation (m)
Net profit (m)
9.0%
12.2%
4.8%
15.0%
5.5%
11.8%
31.7%
11.3%
18.1%
21.7%
24.8%
6.7%
84.2%
1.7%
18.8%
7.7%
9.6%
11.6%
10.0%
13.0%
13.9%
16.4%
16.5%
15.9%
Income tax rate
Net profit margin
8,289
12,040
24,440
18,042
18,085
26,721
9,740
3,388
25,171
4,729
3,408
21,526
4,969
5,871
21,211
20,116
20,681
20,538
11,235
27,210
30,897
5,620
19,359
30,524
4,804
16,661
31,088
8,534
19,429
32,784
11,134
18,252
35,802
9,735
22,044
36,686
Working capital (m)
Long-term debt (m)
Equity (m)
11.7%
9.5%
19.3%
12.1%
10.2%
22.3%
8.1%
6.7%
10.2%
7.2%
7.8%
10.6%
13.2%
12.6%
20.9%
3.6%
4.2%
6.8%
0.8%
4.3%
1.5%
5.2%
5.6%
7.8%
7.6%
7.0%
11.9%
8.2%
7.7%
13.7%
12.2%
11.7%
19.8%
33.8%
23.5%
18.9%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
7,148
10,109
10,192
Receivables
6,414
6,487
6,218
Inventory
5,012
5,157
6,173
Other
1,867
2,346
2,663
Current assets
20,441
24,239
25,224
Acc. Payable
3,946
4,408
4,607
Debt due
220
754
2,251
Other
7,741
7,943
8,631
Current liab.
11,907
13,105
15,489
42.3%
45.8%
37.9%
40.3%
46.6%
73.8%
65.8%
114.1%
41.2%
136.1%
67.4%
198.3%
(9.9)%
99.0%
(287.6)%
60.3%
16.6%
45.1%
38.4%
66.4%
43.0%
51.8%
54.7%
63.6%
Plowback ratio
Div.&Repurch. to FCF
Abbott Laboratories (US) started trading on March 1, 1937 (cik: 0000001800), operates in the Healthcare sector (Medical Devices industry), has 113,000 full-time employees, and is led by Mr. Robert B. Ford. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
9.65%
8.58%
Cash flow
15.07%
20.75%
Earnings
33.24%
53.05%
Dividends
14.05%
16.60%
Book value
4.74%
5.45%
Insider trading
Type
Shares
Date
Woodgrift Randel William
Sale
1,032
03/01/23
Wainer Andrea F
Sale
679
03/01/23
Watkin Jared
Sale
1,198
03/01/23
Tyler Julie L.
Sale
525
03/01/23
Salvadori Daniel Gesua Sive
Sale
1,085
03/01/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
7,726
7,328
8,853
10,701
34,608
2021
10,456
10,223
10,928
11,468
43,075
2022
11,895
11,257
10,410
10,091
43,653
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.32
0.30
0.70
1.22
2.54
2021
1.01
0.67
1.19
1.12
3.99
2022
1.38
1.14
0.81
0.58
3.91
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
0.36
0.36
0.36
0.36
1.45
2021
0.45
0.45
0.45
0.45
1.81
2022
0.47
0.47
0.47
0.46
1.87
02/09/2023
Abbott Laboratories to Acquire Cardiovascular Systems At Equity Value of $890M
The Wall Street Journal - Read more...
01/20/2023
Abbott Under Criminal Probe Over Baby Formula
The Wall Street Journal - Read more...
07/20/2022
Abbott Labs Raises Earnings Outlook as Revenue Climbs
The Wall Street Journal - Read more...
07/10/2022
Baby-Formula Production Restarts at Abbott Plant
The Wall Street Journal - Read more...
06/23/2022
Latest Report of Baby’s Death After Consuming Formula Mentions Cronobacter Bacteria
The Wall Street Journal - Read more...
06/22/2022
FDA Investigating Report of Baby’s Death After Consuming Abbott Formula
The Wall Street Journal - Read more...
06/16/2022
Abbott Halts Production at Michigan Baby-Formula Plant
The Wall Street Journal - Read more...
06/12/2022
Enfamil and Smaller Baby-Formula Brands Test Dominance of Similac
The Wall Street Journal - Read more...
06/08/2022
Abbott Received Earlier Warning on Formula Plant
The Wall Street Journal - Read more...
06/04/2022
Baby-Formula Shortage Expected to Persist Weeks Longer
The Wall Street Journal - Read more...
05/25/2022
FDA Chief Takes Aim at Abbott Laboratories
The Wall Street Journal - Read more...
05/24/2022
Abbott to Release 300,000 Specialty Baby Formula Cans
The Wall Street Journal - Read more...
05/24/2022
Why Is There a Baby Formula Shortage? What to Know and Why It’s Getting Worse
The Wall Street Journal - Read more...
05/22/2022
Abbott CEO Apologizes for Company’s Role in Baby-Formula Shortage
The Wall Street Journal - Read more...
05/17/2022
Gerber Owner Nestlé to Fly Extra Baby Formula to the U.S.
The Wall Street Journal - Read more...
05/12/2022
Baby Formula Shortage Could Leave Parents Scrambling for Months
The Wall Street Journal - Read more...
05/11/2022
Abbott Could Restart Baby Formula Production Within Two Weeks
The Wall Street Journal - Read more...
04/20/2022
Lucky Charms Sickness Complaints Spread Rapidly, Adding Complexity to Safety Probe
The Wall Street Journal - Read more...
04/18/2022
Contaminated-Baby-Formula Investigation Turns Murky
The Wall Street Journal - Read more...
03/02/2022
SoFi Technologies, AMC, Salesforce, Snowflake: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
03/01/2022
Abbott Recalls More Baby Formula
The Wall Street Journal - Read more...
02/18/2022
Abbott Recalls Baby Formula After Reports of Bacterial Contamination
The Wall Street Journal - Read more...
01/26/2022
Abbott’s Rapid Covid-19 Tests Boost Quarterly Sales Growth
The Wall Street Journal - Read more...
01/26/2022
Tesla, Microsoft, Boeing, Texas Instruments: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/20/2021
Novavax, Tesla, Netflix, United: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
04/20/2021
Kansas City Southern, IBM, United Airlines: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...